Publications

Peer reviewed articles:

PUBMED link

  1. Gordts PL, Reekmans S, Lauwers A, Van Dongen A, Verbeek L, Roebroek AJ. Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1258-1264.
  2. Reekmans SM*, PflanznerT, Gordts PL*, Isbert S, Zimmermann P, Annaert W, Weggen S, Roebroek AJ, Pietrzik CU. Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis. Cell Mol Life Sci. 2010;67(1):135-145* Co-first author
  3. Christoffersen C, Pedersen TX, Gordts PL, Roebroek AJ, Dahlbäck B, Nielsen LB. Opposing effects of apoM on catabolism of apoB-containing lipoproteins and atherosclerosis. Circ Res. 2010 May 28;106(10):1624-34
  4. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, Eychmüller A, Gordts PL, Rinninger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011 Feb;17(2):200-5
  5. Deng Y, Foley EM, Gonzales JC, Gordts PL, Li Y, Esko JD. Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology. 2012 Jan;55(1):277-86
  6. Gordts PL, Bartelt A, Nilsson SK, Annaert W, Christoffersen C, Nielsen LB, Heeren J, Roebroek AJ. Impaired LDL receptor-related protein 1 translocation correlates with improved dyslipidemia and atherosclerosis in apoE-deficient mice. PLoS One. 2012;7(6):e38330
  7. Christoffersen C, Benn M, Christensen PM, Gordts PL, Roebroek AJ, Frikke-Schmidt R, Tybjaerg-Hansen A, Dahlbäck B, Nielsen LB. The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. J Lipid Res. 2012 Oct;53(10):2198-204
  8. Lamanna WC, Lawrence R, Sarrazin S, Lameda-Diaz C, Gordts PL, Moremen KW, Esko JD. A genetic model of substrate reduction therapy for mucopolysaccharidosis. J Biol Chem. 2012 Oct 19;287(43):36283-90
  9. Gonzales JC, Gordts PL, Foley EM, Esko JD. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest. 2013 Jun 3;123(6):2742-51.
  10. Foley EM*Gordts PL*, Stanford KI*, Gonzales JC, Lawrence R, Stoddard N, Esko JD. Hepatic Remnant Lipoprotein Clearance by Heparan Sulfate Proteoglycans and Low-Density Lipoprotein Receptors Depend on Dietary Conditions in Mice. Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2065-74. * Co-first author
  11. Gordts PL, Foley EM, Lawrence R, Sinha R, Lameda-Diaz C, Deng L, Nock R, Glass CK, Erbilgin A, Lusis AJ, Witztum JL and Esko JD. Reducing Macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced Type I interferon signaling. Cell Metab. 2014Nov 4;20(5):813–826.
  12. Gordts PL, Esko JD. Heparan Sulfate Proteoglycans Fine-Tune Macrophage Inflammation via IFN-β. CYTOKINE, 2015, doi:10.1016/j.cyto.2014.12.013
  13. Mooij HL, Bernelot Moens SJ, Gordts PL, Stanford KI, Foley EM, van den Boogert MA, Witjes JJ, Hassing HC, Tanck MW, van de Sande MA, Levels JH, Kastelein JJ, Stroes ES, Dallinga-Thie GM, Esko JD, Nieuwdorp M. Genetic Variation in Heparan Sulfate Proteoglycans Modestly Affect Postprandial Lipid Clearance in Humans. J Lipid Res. 2015 Mar;56(3):665-73.
  14. Jimmy Berbee JF, Boon MR, Khedoe PP, Bartelt A,S, Worthmann A, Schlein C, Weigelt C, Kooijman S, Vazirpanah N, Brouwers LPJ, Gordts PL, Esko JD, Hiemstra PS, Havekes LM, Scheja L, Heeren J, Rensen PC.A Central Role for Brown and Beige Adipocytes in Dyslipidemia and Atherosclerosis. Nat Comm. 2015 Mar 10;6:6356.
  15. Akizu N, Cantagrel V, Zaki MS, Wang X, Rosti RO, Dikoglu E, Gelot AB, Rosti B, Vaux KK, Scott EM, Silhavy JL, Schroth J, Copeland B, Schaffer AE, Gordts PL, Esko JD, Buschman M, Napolitano G, Azam M, Al-Gazali L, Selim L, Gamal I, Hadi SA, Mojahedi F, Kayserili H, Masri A, Bastaki L, Temtamy S, Mueller U, Desguerre I, Casanova JL, Gunel M, Gabriel SB, de Lonlay P, Gleeson JG. Biallelic mutations in SNX14 lead to a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Nature Genetics. 2015 May;47(5):528-34
  16. Weiss RJ, Gordts PL, Le D, Xu D, Esko JD, Tor Y. Small molecule antagonists of cell-surface heparan sulfate and heparin–protein interactions.Chem. Sci., 2015, DOI: 10.1039/C5SC01208B
  17. Khalid O, Vera MU, Gordts PL, Ellinwood NM, Schwartz PH, Dickson PI, Esko JD, Wang RY. Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I. PLoS One. 2016 Mar 17;11(3):e0150850.
  18. Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest 2016, Aug:125(8).
  19. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype – An Analysis of 431 239 Patients. Arterioscler Thromb Vasc Biol. 2017, https://doi.org/10.1161/ATVBAHA.116.308704
  20. Yeang C, Gordts PL, Tsimikas S. Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgRKT to the List. Circ Res. 2017 Mar 31;120(7):1050-1052.

Book contributions:

  • Roebroek, AJ, Gordts PL, Reekmans S. Knock-in approaches. Methods Mol Biol. 2011;693:257-75
  • Roebroek, AJ, Gordts PL, Reekmans S. Generation of a series of knockin alleles using RMCE in ES cells. Methods Mol Biol. 2011;693:277-81.

Invited Commentaries and Interviews:

  • Taylor, Jennifer; Gordts, Philip L. S. M. “We Decided to Join Forces to Examine How Macrophage Heparan Sulfate Proteoglycans Impact Atherosclerosis” Source: CIRCULATION, Volume: 125, Issue: 23, Pages: F136-F137, Published: JUN 12 2012
  • Gordts PL, Roebroek AJ. The Full Impact of LRP1 on Atherosclerosis: From Lipid Metabolism to Plaque Rupture. Source: Athero.org, the home of the International Atherosclerosis society (http://www.athero.org/commentaries/comm990.asp)
  • Gordts PL, Esko JD. Heparan sulfate proteoglycans fine-tune macrophage inflammation via IFN-β. Cytokine. 2015 Mar;72(1):118-9.
  • Ramms B and Gordts PL. Dietary nitrate struggles in atherosclerosis. Atherosclerosis. 2016 Feb;245:71-3.